U.S. Residential REITs Stock News

NasdaqGS:PPC
NasdaqGS:PPCFood

Pilgrim's Pride (PPC) Q4 EPS Drop Reinforces Bearish Earnings Decline Narratives

Pilgrim's Pride FY 2025 earnings snapshot Pilgrim's Pride (PPC) has rounded out FY 2025 with Q4 revenue of US$4.5b and EPS of US$0.37, capping a year where trailing 12 month EPS came in at US$4.56 on revenue of US$18.5b. Over recent periods the company has seen quarterly revenue move from US$4.4b in Q4 2024 to roughly US$4.8b in Q2 and Q3 2025 before landing at US$4.5b in Q4 2025, while quarterly EPS has ranged from US$0.99 to US$1.50 through 2024 and early 2025 before the latest print. With...
NasdaqGS:AMCX
NasdaqGS:AMCXMedia

AMC Networks (AMCX) Q4 Loss Challenges Bullish Earnings Narrative Despite New Full Year Profit

AMC Networks (AMCX) closed FY 2025 with Q4 revenue of US$594.8 million and basic EPS of a US$1.26 loss, while trailing twelve month EPS stood at US$2.01 on total revenue of US$2.3 billion and net income of US$89.4 million. Over recent quarters the company has seen revenue range from US$555.2 million to US$600.0 million, with quarterly EPS moving from US$0.40 in Q1 2025 to US$1.73 in Q3 2025 before the Q4 loss. This sets up a picture of earnings that have turned positive on a full year basis...
NYSE:IFF
NYSE:IFFChemicals

IFF (IFF) Returns To Quarterly Profit But Trailing Losses Test Turnaround Narrative

International Flavors & Fragrances FY 2025 earnings snapshot International Flavors & Fragrances (IFF) closed FY 2025 with fourth quarter revenue of US$2,589 million and basic EPS of US$0.07, while trailing twelve month figures show total revenue of US$10.9 billion and a net loss of US$374 million, equal to basic EPS of US$1.46 in losses. Over the past two reported quarters, quarterly revenue moved from US$2,764 million with EPS of US$2.29 in Q2 2025 to US$2,694 million and EPS of US$0.16 in...
NasdaqGS:FRMI
NasdaqGS:FRMISpecialized REITs

Is Fermi (FRMI) Pricing Reflect Its DDM Value After Recent Share Price Swings

If you are wondering whether Fermi's current share price fairly reflects its potential, you are not alone. This article is here to unpack that question in plain terms. Fermi's recent share price of US$9.26 comes after a 28.6% return over the past 7 days, alongside a 10.2% decline over 30 days and a 5.0% return year to date. This mix of moves may leave you questioning how the stock should really be valued. Recent coverage around Fermi has focused on its position in the real estate space and...
NasdaqGS:TMUS
NasdaqGS:TMUSWireless Telecom

T-Mobile US TMUS Margin Compression Reinforces Bearish Narratives Despite EPS Strength

T-Mobile US (TMUS) has wrapped up FY 2025 with fourth quarter revenue of US$24.3 billion and basic EPS of US$1.89, alongside trailing twelve month revenue of US$88.3 billion and EPS of US$9.74 that frame the full year picture. The company has seen quarterly revenue move between US$20.1 billion and US$24.3 billion over the last six reported periods, while basic EPS has ranged from US$1.89 to US$2.84. This sets up a results season where investors are closely watching how these headline figures...
NYSE:TYL
NYSE:TYLSoftware

Tyler Technologies FY 2025 Margin Improvement Tests Bullish Profit Expansion Narrative

Tyler Technologies FY 2025 earnings snapshot Tyler Technologies (TYL) has wrapped up FY 2025 with Q4 revenue of US$575.2 million and basic EPS of US$1.52, while trailing twelve month figures show revenue of about US$2.3 billion and basic EPS of US$7.32, supported by earnings growth of 20% over the past year. The company has seen revenue move from US$2.1 billion and EPS of US$6.17 on a trailing basis a year ago to around US$2.3 billion and EPS of US$7.32, alongside an improvement in net profit...
NYSE:OGN
NYSE:OGNPharmaceuticals

Organon Q3 Net Margin Squeeze Challenges Bullish Earnings Growth Narratives

Organon (OGN) just released its FY 2025 Q3 scorecard, reporting revenue of US$1,602 million and basic EPS of US$0.62, which helps frame how the year is progressing. The company’s revenue has moved from US$1,592 million in Q4 2024 to US$1,594 million in Q2 2025 and US$1,602 million in Q3 2025, while quarterly EPS over that span has ranged from US$0.42 to US$0.62. This gives investors a clearer view of how the top and bottom lines are tracking as margins settle into a tighter range. See our...
NYSE:ASC
NYSE:ASCOil and Gas

Ardmore Shipping (ASC) Margin Reset To 10.3% Challenges Tanker Bull Narratives

Ardmore Shipping (ASC) opened FY 2025 with third quarter revenue of US$81.2 million and basic EPS of US$0.30, alongside net income of US$12.1 million, setting a clear marker for how its product tanker business is currently trading. The company has seen quarterly revenue move from US$121.3 million in Q2 2024 to US$82.0 million in Q4 2024, then to US$74.0 million and US$72.0 million in Q1 and Q2 2025 before reaching US$81.2 million in Q3 2025. EPS over the same stretch shifted from US$1.48 to...
NYSE:BAX
NYSE:BAXMedical Equipment

Baxter International (BAX) Returns To Quarterly Loss And Tests Earnings Recovery Narrative

Baxter International (BAX) has just posted its FY 2025 third quarter numbers, reporting revenue of US$2,835 million and a basic EPS loss of US$0.10. The trailing twelve month EPS stands at a loss of US$0.67 on revenue of US$11.0 billion. The company’s quarterly revenue has moved from US$2,699 million in Q3 2024 to US$2,753 million in Q4 2024, then to US$2,625 million and US$2,810 million in Q1 and Q2 2025. Over the same period, basic EPS shifted from US$0.11 in Q3 2024 to a loss of US$0.94 in...
NYSE:PAYC
NYSE:PAYCProfessional Services

Paycom Software FY 2025 Margin Compression Tests Bullish Long Term Narratives

Paycom Software FY 2025 earnings snapshot Paycom Software (PAYC) has wrapped up FY 2025 with fourth quarter revenue of US$544.3 million and basic EPS of US$2.07, alongside trailing twelve month revenue of about US$2.1 billion and basic EPS of US$8.13. The company has seen quarterly revenue move from US$451.9 million in Q3 2024 to US$544.3 million in Q4 2025, while basic EPS stepped from US$1.31 to US$2.07 over the same stretch. This sets up the latest report as a clean read on how its margins...
NasdaqGS:MLYS
NasdaqGS:MLYSBiotechs

Assessing Mineralys Therapeutics (MLYS) Valuation After Recent Share Price Weakness And Strong 1 Year Return

Event context and recent trading snapshot Mineralys Therapeutics (MLYS) has been drawing attention after recent trading that left the stock around $27.86, with a one-month return of about a 15% decline and a three-month return near a 32% decline. See our latest analysis for Mineralys Therapeutics. That recent 6.45% one day share price decline and softer 7 day and 30 day share price returns come after a much stronger 1 year total shareholder return of 173.14%. Recent momentum appears to be...
NasdaqGS:KELY.A
NasdaqGS:KELY.AProfessional Services

Kelly Services (KELY.A) Q3 Loss Of US$150 Million Tests Margin Expansion Narratives

Kelly Services (KELY.A) has just posted a tough third quarter for FY 2025, with revenue of US$935 million and a basic EPS loss of US$4.25 on net income excluding extra items of a US$150.1 million loss, while trailing twelve month figures show revenue of US$4.4 billion and a basic EPS loss of US$4.43 tied to a US$156.3 million loss. Over the past few quarters, the company has seen revenue move from US$1,038.1 million in Q3 2024 to US$1,191.1 million in Q4 2024, US$1,164.9 million in Q1 2025...
NasdaqCM:ALMU
NasdaqCM:ALMUSemiconductor

Aeluma (ALMU) TTM Loss Of US$3.8m Tests Bullish Profitability Narratives

Aeluma (ALMU) has just posted its Q2 2026 scorecard, with Q1 2026 revenue at about US$1.4 million and a basic EPS loss of US$0.09, alongside trailing twelve month revenue of US$5.6 million and a TTM basic EPS loss of US$0.27 that keeps the story firmly in loss making territory. The company has seen quarterly revenue move from US$0.28 million in Q4 2024 to US$1.39 million in Q1 2026, while quarterly EPS has ranged between a loss of US$0.24 and a profit of US$0.12 over that period, pointing to...
NYSE:CVS
NYSE:CVSHealthcare

CVS Regulatory Pressure Tests PBM Margins And Rite Aid Integration Prospects

CVS Health (NYSE:CVS) is facing increased regulatory and legal pressure tied to its pharmacy benefit manager operations and insurance activities. Recent actions include new PBM transparency reforms, a House Judiciary Committee subpoena focused on Affordable Care Act premium subsidies, and an ongoing Federal Trade Commission lawsuit. These developments come as CVS works through the integration of Rite Aid and Bartell Drugs locations and continues broader operational changes. For investors...
NYSE:VNT
NYSE:VNTElectronic

Vontier (VNT) TTM Margin Dip To 13.3% Tests Bullish Earnings Inflection Narrative

Vontier (VNT) has put solid numbers on the table for FY 2025 so far, with Q3 revenue of US$752.5 million, basic EPS of US$0.70 and trailing twelve month revenue of about US$3.0 billion and EPS of US$2.74, giving investors a clear read on recent performance. The company has seen quarterly revenue move from US$696.4 million in Q2 2024 to US$773.5 million in Q2 2025. Over that span, basic EPS ranged from US$0.45 to US$0.82 and now sits at US$0.70 in Q3 2025. These results are framed by forecasts...
NYSE:IVT
NYSE:IVTRetail REITs

InvenTrust Properties (IVT) FFO Per Share Stability Supports Bullish Cash Flow Narrative

InvenTrust Properties (IVT) has wrapped up FY 2025 with Q4 revenue of US$77.4 million, basic EPS of US$0.03, and funds from operations of US$36.8 million. FFO per share of US$0.47 sets the tone for how investors will read the latest update. Over the past year, total revenue on a trailing twelve month basis has moved from US$274.0 million to US$299.2 million, while basic EPS over the same window has shifted from US$0.19 to US$1.44, supported by net income excluding extra items rising from...
NYSE:SCI
NYSE:SCIConsumer Services

Service Corporation International (SCI) Net Margin Resilience Tests Skeptical Narratives On Profit Quality

Service Corporation International FY 2025 Results Snapshot Service Corporation International (SCI) has wrapped up FY 2025 with fourth quarter revenue of US$1.1 billion and basic EPS of US$1.14, alongside net income of US$159.4 million that caps a trailing 12 month EPS of US$3.83 on revenue of US$4.3 billion. Over the past year, the company has seen quarterly revenue move from US$1.09 billion in Q4 2024 to US$1.11 billion in Q4 2025, while basic EPS shifted from US$1.05 to US$1.14. This sets...
NasdaqGS:UPB
NasdaqGS:UPBBiotechs

Assessing Upstream Bio (UPB) Valuation After Recent Share Price Volatility

Event context and recent stock performance Upstream Bio (UPB) has drawn investor attention after a sharp move in its share price, with the stock down about 13% on the day and weaker over the past week and month. Those short term moves come against a stronger past year, where total return sits around 75%. This raises questions about how investors are weighing the company’s clinical stage respiratory pipeline in relation to its financial profile and recent trading volatility. See our latest...
NYSE:CB
NYSE:CBInsurance

Is It Too Late To Consider Chubb (CB) After Its Recent 25.8% Share Price Gains?

If you are wondering whether Chubb's current share price still offers value, looking closely at how the market is pricing the business versus its fundamentals can be a useful next step. Chubb shares last closed at US$329.07, with returns of 7.3% over the past 30 days and 25.8% over the past year. This may prompt questions about growth potential and how much risk investors are currently pricing in. Recent headlines around Chubb have focused on its position as a major global insurer, its role...
NYSE:WLK
NYSE:WLKChemicals

Does Mizuho’s Downgrade Recast Westlake’s (WLK) Earnings as a Story About Risk Rather Than Resilience?

Westlake Corporation recently announced it will release its fourth quarter and full year 2025 earnings, and held a conference call on February 24, 2026 to discuss the results, with materials made available through its website and webcast. At the same time, a downgrade from Mizuho to a Neutral rating alongside differing analyst opinions has sharpened focus on how experts assess Westlake’s prospects. We’ll now examine how Mizuho’s downgrade and the broader mix of analyst views may influence...
NasdaqGS:PONY
NasdaqGS:PONYSoftware

Pony AI (PONY) Valuation Check As Mixed Short Term Returns Contrast With Long Term DCF Upside

Pony AI (PONY) has drawn interest after recent trading left the stock with mixed short term returns, including a loss of about 9% over the past month and a gain over the past 3 months. See our latest analysis for Pony AI. With Pony AI’s share price at US$14.30, the recent 9.33% 7 day share price return contrasts with a 30 day share price return of 9.03% and a year to date share price return of 11.01%. The 1 year total shareholder return of 3.77% suggests momentum has been uneven rather than...
NasdaqGS:SKWD
NasdaqGS:SKWDInsurance

Is Skyward Specialty Insurance Group (SKWD) Pricing Reflect Its Strong Specialty Insurance Position Today

If you are wondering whether Skyward Specialty Insurance Group is attractively priced at its current level, this article will walk through what the recent numbers might be telling you about value. The share price recently closed at US$46.61, with returns of 6.4% over the last 7 days, 1.1% over the last 30 days, and year to date and 1 year returns of a 4.1% decline and a 4.4% decline, alongside a very large 3 year return of around 2x. Recent headlines around Skyward Specialty Insurance Group...
NYSE:KMT
NYSE:KMTMachinery

Assessing Kennametal (KMT) Valuation After Strong Recent Share Price Momentum

KMT stock triggered by recent performance metrics Kennametal (KMT) has drawn fresh attention after a recent move in its share price, with the stock closing at $40.26 and showing distinct return patterns over the past month and past 3 months. See our latest analysis for Kennametal. The 1 month share price return of 31.05% and 3 month share price return of 45.92%, alongside a 1 year total shareholder return of 86.76%, suggest momentum has been building rather than fading around the current...
NYSE:AOS
NYSE:AOSBuilding

A Look At A. O. Smith (AOS) Valuation After Recent Share Price Momentum

What is moving A. O. Smith (AOS) now? A. O. Smith (AOS) has attracted fresh attention after a solid recent run, with the share price up around 13% over the past month and about 21% in the past 3 months. See our latest analysis for A. O. Smith. That short term strength backs up a steady record, with a 17.42% year to date share price return and a 25.46% 1 year total shareholder return suggesting momentum has been building rather than fading. If A. O. Smith’s recent run has you thinking about...